Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Oak

FuturHealth
Graded #215

Lower grade

vs+10.300000000000011
Oak
Graded #42

Higher grade

The verdict

Oak takes it — 75.9/100 to 65.6/100.

Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +36
60
96
Dose & formulationFuturHealth +19
81
62
Clinical oversightFuturHealth +1
67
66
Labs & monitoringFuturHealth +3
61
58
FulfillmentOak +26
62
88
Contract termsOak +33
55
88
FuturHealth · left barOak · right bar

The numbers

MetricFuturHealthOak
WeighScore65.6/10075.9/100
GradeCC
Scorecard rank#215#42
Semaglutide$199/mo (compounded)From $119/mo
TirzepatideNot disclosedFrom $185/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Oak

Graded #42 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard